TrialLeukemia & lymphoma2024

Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.

Yun Kyoung Ryu Tiger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.